It is presented that dasatinib (DAS), a multikinase inhibitor, promotes the cleavage and secretion of the GSDMD and GSDME which induce the pyroptosis of A549 cells, which thus inhibits the progress of NSCLC [83]. Here, GSDMD is linked to non-small cell lung carcinoma.